DrugPatentWatch Database Preview

Eli Lilly And Co Company Profile

« Back to Dashboard

What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?

ELI LILLY AND CO has seven approved drugs.

There are thirteen US patents protecting ELI LILLY AND CO drugs.

There are one hundred and seventy-three patent family members on ELI LILLY AND CO drugs in forty-nine countries and fifty-one supplementary protection certificates in twelve countries.

Summary for Eli Lilly And Co

International Patents:	173
US Patents:	13
Tradenames:	8
Ingredients:	7
NDAs:	7
Drug Master File Entries:	36
Patent Litigation for Eli Lilly And Co:	See patent lawsuits for Eli Lilly And Co
PTAB Cases with Eli Lilly And Co as patent owner:	See PTAB cases with Eli Lilly And Co as patent owner

Drugs and US Patents for Eli Lilly And Co

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-001	Sep 28, 2017		RX	Yes	No
Eli Lilly And Co	EFFIENT	prasugrel hydrochloride	TABLET;ORAL	022307-001	Jul 10, 2009	AB	RX	Yes	No
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No	9,289,586
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-003	Jun 15, 1999	AB	RX	Yes	Yes

Expired US Patents for Eli Lilly And Co

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-006	Dec 23, 1992	4,626,549*PED
Eli Lilly And Co	HUMALOG KWIKPEN	insulin lispro recombinant	SOLUTION;SUBCUTANEOUS	205747-001	May 26, 2015	6,551,992
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-004	Jun 15, 1999	4,626,549*PED
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-004	Jun 15, 1999	4,314,081*PED

Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Topical Solution	30 mg/1.5 mL		2013-01-29
	Tablets	5 mg and 10 mg		2013-07-10

Non-Orange Book US Patents for Eli Lilly And Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,177,449	Spreading implement
6,906,028	Stable insulin formulations
8,357,393	Transdermal delivery rate control using amorphous pharmaceutical compositions
7,427,275	Medication dispensing apparatus with triple screw threads for mechanical advantage

International Patents for Eli Lilly And Co Drugs

Country	Document Number	Estimated Expiration
South Africa	200711040
Taiwan	I293249
Taiwan	201031653
Taiwan	I429635

Supplementary Protection Certificates for Eli Lilly And Co Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0020	France		PRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110
/2000	Austria		PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 - EU/1/00/134/007 20000609
00597	Netherlands		PRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121
34/2000	Austria		PRODUCT NAME: LANTUS - INSULIN GLARGIN

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Eli Lilly And Co
• Eli Lilly Co